Peter de Waele
Chief Executive Officer at Advanced Therapies Consulting Limited
Profile
Peter de Waele is the founder of Xcellentis NV, which was founded in 2001, where he held the title of Chief Operating Officer in 2006.
He is currently the Managing Director at Advanced Therapies Consulting Limited.
Dr. de Waele's former positions include Chief Therapeutics Officer at Fujirebio Europe NV, Assistant Professor at Ghent University in 1986, and Vice President-Research & Development at Celyad Oncology SA from 2010 to 2017.
Dr. de Waele received his graduate and doctorate degrees from Ghent University.
Peter de Waele active positions
Companies | Position | Start |
---|---|---|
Advanced Therapies Consulting Limited | Chief Executive Officer | - |
Former positions of Peter de Waele
Companies | Position | End |
---|---|---|
CELYAD ONCOLOGY SA | Chief Tech/Sci/R&D Officer | - |
Xcellentis NV | Founder | 2005-12-31 |
Ghent University | Corporate Officer/Principal | 1985-12-31 |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Corporate Officer/Principal | - |
Training of Peter de Waele
Ghent University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
CELYAD ONCOLOGY SA | Health Technology |
Private companies | 3 |
---|---|
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Health Technology |
Xcellentis NV | Health Technology |
Advanced Therapies Consulting Limited |
- Stock Market
- Insiders
- Peter de Waele